(7) day supply if clinically necessary, but said supply must be issued in accordance with Title 21 CFR § 1306.12 Refilling prescriptions; issuance of multiple prescriptions (i.e., the prescription must be dated on the date of issuance with ‘do not fill until’ noting the date the prescription may be filled), and such need for an additional seven (7) day supply must be documented in the chart.

I. When prescribing opioids for either chronic or acute pain, it shall be considered a contraindication to prescribe opioids concurrently with Benzodiazepines and/or Soma. However, opioids and benzodiazepines may be prescribed concurrently on a very short term basis, and in accordance with section H of this rule, when an acute injury requiring opioids occurs. The need for such concurrent prescribing must be documented appropriately in the chart. Patients who are currently on an established regimen of concomitant opioids and benzodiazepines may be allotted a reasonable period of time to withdraw from one or both substances.

J. When a licensee treats chronic noncancerous pain and/or psychiatric conditions outside the definition of a pain management practice (Rule 1.2) (G) the licensee shall actively utilize the MPMP upon initial contact with a new patient and every 3 months thereafter on any and all patients who are prescribed, administered, or dispensed controlled substances. Reports generated on patients shall span the length of time from the previous review of the MPMP so that adequate information is obtained to determine the patient’s compliance for treatment. Documentation, such as a copy of the report itself and/or reflections in the charts dictation and/or notes shall be kept within the patient’s record and made available for inspection upon request. In addition, licensees required to register under this section shall also utilize the MPMP to generate a global report to review the entire practice as a whole at least yearly. Documentation of the global report shall be kept in a separate file to be available for inspection upon request.

K. Point of service drug testing must be done each time a Schedule II medication is written for the treatment of chronic non-cancer pain. Point of service drug testing and MPMP review must be done at least every ninety (90) days for patients prescribed benzodiazepines for chronic medical and/or psychiatric conditions.

M-L. The use of Methadone to treat chronic and/or acute non-cancer pain is prohibited.


Rule 1.8 Drug Maintenance Requirements. All drug products which are maintained or stored in the office of a physician’s office shall be maintained or stored in the manufacturer's or re-packer's original container. The label of any container in which drugs are maintained must bear the drug name, strength, the manufacturer's control lot number and the expiration date. Drugs which are pre-counted and prepackaged for purposes of dispensing shall be identifiable as to expiration date and manufacturer's control lot number. The containers in which drug products are maintained shall not be labeled in any false or misleading manner. The labeling requirements of this rule are in addition to, and not in lieu of, other labeling requirements of the Laws of the state of Mississippi, Rules of the Mississippi State Board of Medical Licensure, and Laws of the United States or Federal